These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38173839)

  • 21. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.
    Sun LP; Bai WQ; Zhou DD; Wu XF; Zhang LW; Cui AL; Xie ZH; Gao RJ; Zhen YS; Li ZR; Miao QF
    J Med Chem; 2023 Nov; 66(21):14700-14715. PubMed ID: 37883180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
    Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
    Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corrigendum: Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating Pi3K/AKT pathway through the
    Zhang J; Tang Z; Guo X; Wang Y; Zhou Y; Cai W
    Front Oncol; 2023; 13():1303608. PubMed ID: 38023118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
    Chang CH; Wang Y; Zalath M; Liu D; Cardillo TM; Goldenberg DM
    Mol Cancer Ther; 2016 Aug; 15(8):1910-9. PubMed ID: 27207776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody.
    Nishimura T; Mitsunaga M; Sawada R; Saruta M; Kobayashi H; Matsumoto N; Kanke T; Yanai H; Nakamura K
    Cancer Med; 2019 Dec; 8(18):7781-7792. PubMed ID: 31674732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
    Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
    Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
    Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
    Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
    Goldenberg DM; Cardillo TM; Govindan SV; Rossi EA; Sharkey RM
    Oncotarget; 2015 Sep; 6(26):22496-512. PubMed ID: 26101915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
    Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
    Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.
    Shvartsur A; Bonavida B
    Genes Cancer; 2015 Mar; 6(3-4):84-105. PubMed ID: 26000093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
    Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
    Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
    Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma
    Donovan J; Deng Z; Bian F; Shukla S; Gomez-Arroyo J; Shi D; Kalinichenko VV; Kalin TV
    Front Oncol; 2023; 13():1163510. PubMed ID: 37124500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor.
    Gu Y; Sai Y; Wang J; Yu M; Wang G; Zhang L; Ren H; Fan S; Ren Y; Qing W; Su W
    Eur J Pharm Sci; 2019 Aug; 136():104938. PubMed ID: 31132401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.
    Liu X; Deng J; Yuan Y; Chen W; Sun W; Wang Y; Huang H; Liang B; Ming T; Wen J; Huang B; Xing D
    Pharmacol Ther; 2022 Nov; 239():108296. PubMed ID: 36208791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo.
    Liu J; Yang D; Yin Z; Gao M; Tong H; Su Y; Zhu J; Ye C; Zhang H
    Biochem Biophys Res Commun; 2019 Apr; 512(2):276-282. PubMed ID: 30879767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
    Sharkey RM; McBride WJ; Cardillo TM; Govindan SV; Wang Y; Rossi EA; Chang CH; Goldenberg DM
    Clin Cancer Res; 2015 Nov; 21(22):5131-8. PubMed ID: 26106073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corrigendum: Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma.
    Liu H; Xu Y; Liang K; Liu R
    Front Oncol; 2021; 11():817747. PubMed ID: 35004334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer.
    Zhao W; Jia L; Zhang M; Huang X; Qian P; Tang Q; Zhu J; Feng Z
    Am J Cancer Res; 2019; 9(8):1846-1856. PubMed ID: 31497363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.